febuxostat has been researched along with lapatinib in 3 studies
| Studies (febuxostat) | Trials (febuxostat) | Recent Studies (post-2010) (febuxostat) | Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) |
|---|---|---|---|---|---|
| 818 | 133 | 710 | 1,919 | 305 | 1,442 |
| Protein | Taxonomy | febuxostat (IC50) | lapatinib (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 7.375 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 0.0827 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 0.0537 | |
| Platelet-derived growth factor receptor beta | Homo sapiens (human) | 8.5 | |
| D(1A) dopamine receptor | Sus scrofa (pig) | 0.06 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 1 | |
| Receptor tyrosine-protein kinase erbB-4 | Homo sapiens (human) | 0.1659 | |
| Alpha-1A adrenergic receptor | Sus scrofa (pig) | 0.06 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 3.2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
2 review(s) available for febuxostat and lapatinib
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
1 other study(ies) available for febuxostat and lapatinib
| Article | Year |
|---|---|
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |